$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 ... 6 7 8 9 10 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.71 | 7,300 | 216,883 | 27,856 | 35.2 K to 27.9 K (-20.76 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 35,156 | 27.7 K to 35.2 K (+27.12 %) |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 6,000 | 2,880 | 53,765 | |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.97 | 6,000 | 185,820 | 15,858 | 21.9 K to 15.9 K (-27.45 %) |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 6,000 | 2,880 | 21,858 | 15.9 K to 21.9 K (+37.84 %) |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.99 | 1,500 | 46,485 | 34,500 | 36 K to 34.5 K (-4.17 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 20,000 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.27 | 200 | 6,454 | 41,890 | 42.1 K to 41.9 K (-0.48 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 31.51 | 1,800 | 56,718 | 42,090 | 43.9 K to 42.1 K (-4.10 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.13 | 500 | 16,065 | 43,890 | 44.4 K to 43.9 K (-1.13 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 31.23 | 6,500 | 202,995 | 44,390 | 50.9 K to 44.4 K (-12.77 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 50,890 | 45.9 K to 50.9 K (+10.90 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 31.68 | 500 | 15,840 | 36,000 | 36.5 K to 36 K (-1.37 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 32.23 | 100 | 3,223 | 15,858 | 16 K to 15.9 K (-0.63 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 31.47 | 1,900 | 59,793 | 15,958 | 17.9 K to 16 K (-10.64 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 48,750 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 11,875 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.19 | 391 | 12,586 | 27,656 | 28 K to 27.7 K (-1.39 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 31.48 | 7,109 | 223,791 | 28,047 | 35.2 K to 28 K (-20.22 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 35,156 | 27.7 K to 35.2 K (+27.12 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.35 | 100 | 3,235 | 27,656 | 27.8 K to 27.7 K (-0.36 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 31.49 | 2,400 | 75,576 | 27,756 | 30.2 K to 27.8 K (-7.96 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 30,156 | 27.7 K to 30.2 K (+9.04 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.20 | 287 | 9,241 | 206,500 | 206.8 K to 206.5 K (-0.14 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.49 | 9,713 | 305,862 | 206,787 | 216.5 K to 206.8 K (-4.49 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.23 | 100 | 3,223 | 216,500 | 216.6 K to 216.5 K (-0.05 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.51 | 4,900 | 154,399 | 216,600 | 221.5 K to 216.6 K (-2.21 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 205,751 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,000 | 11,640 | 212,751 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.17 | 286 | 9,201 | 0 | 286 to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.49 | 6,714 | 211,424 | 286 | 7 K to 286 (-95.91 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.27 | 100 | 3,227 | 0 | 100 to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.48 | 2,900 | 91,292 | 100 | 3 K to 100 (-96.67 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,000 | 11,640 | 3,000 | 0 to 3 K |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 55,500 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 23,500 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 32.20 | 900 | 28,980 | 0 | 900 to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 31.29 | 6,100 | 190,869 | 900 | 7 K to 900 (-87.14 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 31.49 | 2,000 | 62,980 | 0 | 2 K to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| May 07 2014 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Sell | S | 42.86 | 313,491 | 13,436,224 | 2,819,743 | 3.1 M to 2.8 M (-10.01 %) |
| May 07 2014 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | S | 42.86 | 313,491 | 13,436,224 | 2,819,743 | 3.1 M to 2.8 M (-10.01 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 42.86 | 12,263 | 525,592 | 60,496 | 72.8 K to 60.5 K (-16.85 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 42.86 | 202,879 | 8,695,394 | 1,000,841 | 1.2 M to 1 M (-16.85 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 42.86 | 215,644 | 9,242,502 | 1,939,031 | 2.2 M to 1.9 M (-10.01 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | P | 42.86 | 1,100,000 | 47,146,000 | 4,572,887 | 3.5 M to 4.6 M (+31.67 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 31.45 | 48,713 | 1,532,024 | 72,759 | 121.5 K to 72.8 K (-40.10 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 31.45 | 805,905 | 25,345,712 | 1,203,720 | 2 M to 1.2 M (-40.10 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 33.81 | 1,351 | 45,677 | 121,472 | 122.8 K to 121.5 K (-1.10 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 33.81 | 22,349 | 755,620 | 2,009,625 | 2 M to 2 M (-1.10 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 35.89 | 6,936 | 248,933 | 122,823 | 129.8 K to 122.8 K (-5.35 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 35.89 | 114,746 | 4,118,234 | 2,031,974 | 2.1 M to 2 M (-5.35 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 25,500 | |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 36.13 | 500 | 18,065 | 0 | 500 to 0 (-100.00 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 35.75 | 1,500 | 53,625 | 500 | 2 K to 500 (-75.00 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 14,375 | |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 36.17 | 700 | 25,319 | 27,656 | 28.4 K to 27.7 K (-2.47 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 35.75 | 1,800 | 64,350 | 28,356 | 30.2 K to 28.4 K (-5.97 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 30,156 | 27.7 K to 30.2 K (+9.04 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.86 | 2,000 | 71,720 | 45,890 | 47.9 K to 45.9 K (-4.18 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 35.75 | 1,000 | 35,750 | 36,500 | 37.5 K to 36.5 K (-2.67 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 36.08 | 1,936 | 69,851 | 15,922 | 17.9 K to 15.9 K (-10.84 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 35.64 | 2,064 | 73,561 | 17,858 | 19.9 K to 17.9 K (-10.36 %) |
| Jan 29 2014 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | P | 50.00 | 300,000 | 15,000,000 | 3,472,887 | 3.2 M to 3.5 M (+9.46 %) |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 24.11 | 20,000 | 482,200 | 20,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | A | 24.11 | 29,000 | 699,190 | 29,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | A | 24.11 | 29,000 | 699,190 | 29,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | A | 24.11 | 29,000 | 699,190 | 29,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | A | 24.11 | 29,000 | 699,190 | 29,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 24.11 | 29,000 | 699,190 | 29,000 | |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | A | 24.11 | 110,000 | 2,652,100 | 110,000 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | C | 0.00 | 79,617 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | J | 0.00 | 118,240 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | C | 0.00 | 39,175 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | C | 0.00 | 293,143 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | C | 0.00 | 507,665 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Option Exercise | C | 0.00 | 1,376,249 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Buy | C | 0.00 | 79,617 | 0 | 2,496,152 | 2.4 M to 2.5 M (+3.29 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Buy | J | 0.00 | 190,571 | 0 | 2,416,535 | 2.2 M to 2.4 M (+8.56 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Buy | C | 0.00 | 39,175 | 0 | 2,225,964 | 2.2 M to 2.2 M (+1.79 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Buy | C | 0.00 | 293,143 | 0 | 2,186,789 | 1.9 M to 2.2 M (+15.48 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Buy | C | 0.00 | 507,665 | 0 | 1,893,646 | 1.4 M to 1.9 M (+36.63 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | EVNIN ANTHONY B | Director | Buy | C | 0.00 | 1,376,249 | 0 | 1,385,981 | 9.7 K to 1.4 M (+14,141.48 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Option Exercise | C | 0.00 | 1,990,446 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Option Exercise | J | 0.00 | 36,496 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Option Exercise | C | 0.00 | 457,875 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | P | 15.00 | 666,667 | 10,000,005 | 3,172,887 | 2.5 M to 3.2 M (+26.60 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | C | 0.00 | 1,990,446 | 0 | 2,506,220 | 515.8 K to 2.5 M (+385.91 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | J | 0.00 | 57,899 | 0 | 515,774 | 457.9 K to 515.8 K (+12.65 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | C | 0.00 | 457,875 | 0 | 457,875 | 0 to 457.9 K |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | C | 0.00 | 60,245 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | C | 0.00 | 39,175 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | C | 0.00 | 293,144 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | C | 0.00 | 507,666 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Option Exercise | C | 0.00 | 1,376,249 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | C | 0.00 | 60,245 | 0 | 2,281,346 | 2.2 M to 2.3 M (+2.71 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | C | 0.00 | 39,175 | 0 | 2,221,101 | 2.2 M to 2.2 M (+1.80 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | C | 0.00 | 293,144 | 0 | 2,181,926 | 1.9 M to 2.2 M (+15.52 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | C | 0.00 | 507,666 | 0 | 1,888,782 | 1.4 M to 1.9 M (+36.76 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Buy | C | 0.00 | 1,376,249 | 0 | 1,381,116 | 4.9 K to 1.4 M (+28,277.15 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Option Exercise | C | 0.00 | 95,541 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Option Exercise | J | 0.00 | 172,188 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Option Exercise | C | 0.00 | 48,577 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Option Exercise | C | 0.00 | 363,495 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Option Exercise | C | 0.00 | 629,499 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Option Exercise | C | 0.00 | 1,706,532 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Buy | C | 0.00 | 95,541 | 0 | 3,133,234 | 3 M to 3.1 M (+3.15 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Buy | J | 0.00 | 277,520 | 0 | 3,037,693 | 2.8 M to 3 M (+10.05 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Buy | C | 0.00 | 48,577 | 0 | 2,760,173 | 2.7 M to 2.8 M (+1.79 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Buy | C | 0.00 | 363,495 | 0 | 2,711,596 | 2.3 M to 2.7 M (+15.48 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Buy | C | 0.00 | 629,499 | 0 | 2,348,101 | 1.7 M to 2.3 M (+36.63 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Buy | C | 0.00 | 1,706,532 | 0 | 1,718,602 | 12.1 K to 1.7 M (+14,138.62 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | C | 0.00 | 95,541 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | J | 0.00 | 172,188 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | C | 0.00 | 48,577 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | C | 0.00 | 363,495 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | C | 0.00 | 629,499 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | C | 0.00 | 1,706,532 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | C | 0.00 | 95,541 | 0 | 3,133,234 | 3 M to 3.1 M (+3.15 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | J | 0.00 | 277,520 | 0 | 3,037,693 | 2.8 M to 3 M (+10.05 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | C | 0.00 | 48,577 | 0 | 2,760,173 | 2.7 M to 2.8 M (+1.79 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | C | 0.00 | 363,495 | 0 | 2,711,596 | 2.3 M to 2.7 M (+15.48 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | C | 0.00 | 629,499 | 0 | 2,348,101 | 1.7 M to 2.3 M (+36.63 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Buy | C | 0.00 | 1,706,532 | 0 | 1,718,602 | 12.1 K to 1.7 M (+14,138.62 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | C | 0.00 | 714 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | C | 0.00 | 5,348 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | C | 0.00 | 9,261 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | C | 0.00 | 25,108 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | C | 0.00 | 714 | 0 | 265,431 | 264.7 K to 265.4 K (+0.27 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | C | 0.00 | 5,348 | 0 | 264,717 | 259.4 K to 264.7 K (+2.06 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | C | 0.00 | 9,261 | 0 | 259,369 | 250.1 K to 259.4 K (+3.70 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Buy | C | 0.00 | 25,108 | 0 | 250,108 | 225 K to 250.1 K (+11.16 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | C | 0.00 | 64,019 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | J | 0.00 | 138,862 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | C | 0.00 | 39,172 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | C | 0.00 | 293,142 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | C | 0.00 | 507,664 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | C | 0.00 | 1,376,248 | 0 | 0 | |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Buy | C | 0.00 | 64,019 | 0 | 2,513,783 | 2.4 M to 2.5 M (+2.61 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Buy | J | 0.00 | 223,806 | 0 | 2,449,764 | 2.2 M to 2.4 M (+10.05 %) |
| Sep 26 2013 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Buy | C | 0.00 | 39,172 | 0 | 2,225,958 | 2.2 M to 2.2 M (+1.79 %) |